Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04159688 · ClinicalTrials.gov registry record · Early Phase 1
Imaging Glutamate Release From Alcohol
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT04159688: Completed Early Phase 1 study, sponsored by Yale University.
NCT04159688 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04159688, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of this research project is to determine the sensitivity of PET radioligands specific for targets in the glutamate system to an alcohol challenge.
Primary Outcome
The percent change in receptor availability will be measured from the PET data. Since this project is for basic science it is not known whether positive values are better or worse outcome.
Interventions
- DRUG Alcohol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2022-06-30 |
| Phase | Early Phase 1 |
What the finished NCT04159688 record still lists
NCT04159688 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Alcohol is the first listed.
NCT04159688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04159688 about?
NCT04159688 is a clinical study titled "Imaging Glutamate Release From Alcohol". The goal of this research project is to determine the sensitivity of PET radioligands specific for targets in the glutamate system to an alcohol challenge.
What is the current status of trial NCT04159688?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2020-03-01. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04159688?
The interventions under investigation include: Alcohol (DRUG).
Who is sponsoring clinical trial NCT04159688?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04159688's enrollment target sits among peer trials
8 1782nd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI